150 related articles for article (PubMed ID: 18771701)
1. alpha-Galactosylceramide enhances the protective and therapeutic effects of tumor cell based vaccines for ovarian tumors.
Choi YS; Hoory T; Monie A; Wu A; Connolly D; Hung CF
Vaccine; 2008 Oct; 26(46):5855-63. PubMed ID: 18771701
[TBL] [Abstract][Full Text] [Related]
2. Transient Foxp3(+) regulatory T-cell depletion enhances therapeutic anticancer vaccination targeting the immune-stimulatory properties of NKT cells.
Mattarollo SR; Steegh K; Li M; Duret H; Foong Ngiow S; Smyth MJ
Immunol Cell Biol; 2013 Jan; 91(1):105-14. PubMed ID: 23090488
[TBL] [Abstract][Full Text] [Related]
3. alpha-Galactosylceramide can act as a nasal vaccine adjuvant inducing protective immune responses against viral infection and tumor.
Ko SY; Ko HJ; Chang WS; Park SH; Kweon MN; Kang CY
J Immunol; 2005 Sep; 175(5):3309-17. PubMed ID: 16116223
[TBL] [Abstract][Full Text] [Related]
4. The Adjuvant of α-Galactosylceramide Presented by Gold Nanoparticles Enhances Antitumor Immune Responses of MUC1 Antigen-Based Tumor Vaccines.
Liu Y; Wang Z; Yu F; Li M; Zhu H; Wang K; Meng M; Zhao W
Int J Nanomedicine; 2021; 16():403-420. PubMed ID: 33469292
[TBL] [Abstract][Full Text] [Related]
5. Cancer immunotherapy using irradiated tumor cells secreting heat shock protein 70.
Chang CL; Tsai YC; He L; Wu TC; Hung CF
Cancer Res; 2007 Oct; 67(20):10047-57. PubMed ID: 17942939
[TBL] [Abstract][Full Text] [Related]
6. Natural killer T cell ligand alpha-galactosylceramide enhances protective immunity induced by malaria vaccines.
Gonzalez-Aseguinolaza G; Van Kaer L; Bergmann CC; Wilson JM; Schmieg J; Kronenberg M; Nakayama T; Taniguchi M; Koezuka Y; Tsuji M
J Exp Med; 2002 Mar; 195(5):617-24. PubMed ID: 11877484
[TBL] [Abstract][Full Text] [Related]
7. DNA vaccine with α-galactosylceramide at prime phase enhances anti-tumor immunity after boosting with antigen-expressing dendritic cells.
Kim D; Hung CF; Wu TC; Park YM
Vaccine; 2010 Oct; 28(45):7297-305. PubMed ID: 20817010
[TBL] [Abstract][Full Text] [Related]
8. NKT cell adjuvant-based tumor vaccine for treatment of myc oncogene-driven mouse B-cell lymphoma.
Mattarollo SR; West AC; Steegh K; Duret H; Paget C; Martin B; Matthews GM; Shortt J; Chesi M; Bergsagel PL; Bots M; Zuber J; Lowe SW; Johnstone RW; Smyth MJ
Blood; 2012 Oct; 120(15):3019-29. PubMed ID: 22932803
[TBL] [Abstract][Full Text] [Related]
9. Combination of the toll like receptor agonist and α-Galactosylceramide as an efficient adjuvant for cancer vaccine.
Gableh F; Saeidi M; Hemati S; Hamdi K; Soleimanjahi H; Gorji A; Ghaemi A
J Biomed Sci; 2016 Jan; 23():16. PubMed ID: 26811064
[TBL] [Abstract][Full Text] [Related]
10. Synthetic TRP2 long-peptide and α-galactosylceramide formulated into cationic liposomes elicit CD8+ T-cell responses and prevent tumour progression.
Neumann S; Young K; Compton B; Anderson R; Painter G; Hook S
Vaccine; 2015 Oct; 33(43):5838-5844. PubMed ID: 26363382
[TBL] [Abstract][Full Text] [Related]
11. Essential role of bystander cytotoxic CD122+CD8+ T cells for the antitumor immunity induced in the liver of mice by alpha-galactosylceramide.
Nakagawa R; Inui T; Nagafune I; Tazunoki Y; Motoki K; Yamauchi A; Hirashima M; Habu Y; Nakashima H; Seki S
J Immunol; 2004 Jun; 172(11):6550-7. PubMed ID: 15153469
[TBL] [Abstract][Full Text] [Related]
12. Interleukin-2 gene transfer potentiates the alpha-galactosylceramide-stimulated antitumor effect by the induction of TRAIL in NKT and NK cells in mouse models of subcutaneous and metastatic carcinoma.
Nishihori Y; Kato K; Tanaka M; Okamoto T; Hagiwara S; Araki N; Kogawa K; Kuribayashi K; Nakamura K; Niitsu Y
Cancer Biol Ther; 2009 Sep; 8(18):1763-70. PubMed ID: 19901518
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant use of the NKT cell agonist alpha-galactosylceramide leads to enhancement of M2-based DNA vaccine immunogenicity and protective immunity against influenza A virus.
Fotouhi F; Shaffifar M; Farahmand B; Shirian S; Saeidi M; Tabarraei A; Gorji A; Ghaemi A
Arch Virol; 2017 May; 162(5):1251-1260. PubMed ID: 28120096
[TBL] [Abstract][Full Text] [Related]
14. Enhancement of HIV DNA vaccine immunogenicity by the NKT cell ligand, alpha-galactosylceramide.
Huang Y; Chen A; Li X; Chen Z; Zhang W; Song Y; Gurner D; Gardiner D; Basu S; Ho DD; Tsuji M
Vaccine; 2008 Mar; 26(15):1807-16. PubMed ID: 18329757
[TBL] [Abstract][Full Text] [Related]
15. An α-GalCer analogue with branched acyl chain enhances protective immune responses in a nasal influenza vaccine.
Lee YS; Lee KA; Lee JY; Kang MH; Song YC; Baek DJ; Kim S; Kang CY
Vaccine; 2011 Jan; 29(3):417-25. PubMed ID: 21087689
[TBL] [Abstract][Full Text] [Related]
16. Activated iNKT cells promote memory CD8+ T cell differentiation during viral infection.
Reilly EC; Thompson EA; Aspeslagh S; Wands JR; Elewaut D; Brossay L
PLoS One; 2012; 7(5):e37991. PubMed ID: 22649570
[TBL] [Abstract][Full Text] [Related]
17. Enhancement of therapeutic DNA vaccine potency by melatonin through inhibiting VEGF expression and induction of antitumor immunity mediated by CD8+ T cells.
Baghban Rahimi S; Mohebbi A; Vakilzadeh G; Biglari P; Razeghi Jahromi S; Mohebi SR; Shirian S; Gorji A; Ghaemi A
Arch Virol; 2018 Mar; 163(3):587-597. PubMed ID: 29149434
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms of the antimetastatic effect in the liver and of the hepatocyte injury induced by alpha-galactosylceramide in mice.
Nakagawa R; Nagafune I; Tazunoki Y; Ehara H; Tomura H; Iijima R; Motoki K; Kamishohara M; Seki S
J Immunol; 2001 Jun; 166(11):6578-84. PubMed ID: 11359810
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of pH-sensitive fusogenic polymer-modified liposomes co-loaded with antigen and α-galactosylceramide as an anti-tumor vaccine.
Okazaki S; Iwasaki T; Yuba E; Watarai S
J Vet Med Sci; 2018 Feb; 80(2):197-204. PubMed ID: 29311431
[TBL] [Abstract][Full Text] [Related]
20. Intra-peritoneal hyperthermia combining α-galactosylceramide in the treatment of ovarian cancer.
Wu CC; Chuang YT; Hsu YT; Huang JT; Wu TC; Hung CF; Yang YC; Chang CL
PLoS One; 2013; 8(7):e69336. PubMed ID: 23935988
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]